433 results on '"Riisnaes, Ruth"'
Search Results
102. A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1
103. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
104. Systematic study of tissue factor expression in solid tumors.
105. HER3 Is an Actionable Target in Advanced Prostate Cancer
106. Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787)
107. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
108. Abstract CT161: A homologous recombination repair (HRR) functional assay to stratify patients with metastatic prostate cancer for PARP inhibitor treatment in the TOPARP-B clinical trial
109. Abstract LB035: B7-H3 as a therapeutic target in prostate cancer
110. Abstract CT120: Results of the glioblastoma multiforme (GBM) cohort of phase 1 trial Ice-CAP (NCT03673787): Preliminary evidence of antitumour activity of Ipatasertib (Ipa) and Atezolizumab (A) in patients (pts) with PTEN loss
111. HER3 expression and MEK activation in non-small-cell lung carcinoma
112. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
113. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
114. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
115. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers
116. Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).
117. JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
118. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
119. Characterizing CDK12-Mutated Prostate Cancers
120. Elucidating Durable Responses to Immune Checkpoint Inhibition
121. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
122. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
123. HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer
124. Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers
125. Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors
126. Abstract LB-075: CDK12-mutated lethal prostate cancers: How hot are these tumors
127. Abstract CT140: Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation study of Ipatasertib (Ipa) in combination with atezolizumab (A) in patients (pts) with advanced solid tumors (Ice-CAP)
128. A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.
129. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
130. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
131. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
132. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
133. PSMA heterogeneity and DNA repair defects in prostate cancer.
134. Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
135. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
136. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
137. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
138. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
139. Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
140. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
141. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
142. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
143. Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.
144. The prognostic and predictive value of AR-V7 quantification in mCRPC.
145. Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.
146. NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA).
147. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
148. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
149. Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
150. Author response: Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.